Te-Chun Hsia1, Chih-Yen Tu1, Hsin-Yuan Fang1, Ji-An Liang1, Chia-Chin Li1, Chun-Ru Chien1. 1. 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 40402, Taiwan ; 2 Department of Respiratory Therapy, College of Health Care, 3 School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan ; 4 Department of Chest Surgery, 5 Department of Radiation Oncology, 6 Cancer Center, China Medical University Hospital, Taichung 40402, Taiwan.
Abstract
BACKGROUND: Image-guided radiotherapy (IGRT) is a novel technology to enhance RT delivery accuracy. However, the clinical effectiveness and cost-effectiveness are less clear. The aim of our study is to compare the cost and effectiveness of conventional fractionated RT for non-operated localized lung cancer delivered with vs. without IGRT via this population-based propensity score (PS) matched analysis. METHODS: We identified eligible patients diagnosed within 2007-2010 through a comprehensive population-based database containing cancer, death registries, and reimbursement data in Taiwan. The primary duration of interest (DOI) was 2 years within diagnosis. Effectiveness was measured as survival whereas direct medical cost was measured from the payers' perspective. In supplementary analysis (SA), we estimated the cost-effectiveness in consider of out-of-pocket (OOP) payment and 4 years as DOI. RESULTS: Our study population constituted 124 patients. Within 2 years, both the mean cost (2014 USD) and survival (life-year, LY) were higher for IGRT ($60,774 vs. $60,554; 1.43 vs. 1.37). The incremental cost-effectiveness ratio (ICER) when IGRT was compared to non-IGRT was 3,667 (USD/LY). The chance for IGRT to be cost-effective was around 68% & 70% at willingness-to-pay threshold 50,000 USD/LY and 150,000 USD/LY respectively. IGRT remained cost-effective in SA. CONCLUSIONS: We provide the first empirical evidence that when compared to non-IGRT, IGRT was potentially cost-effective.
BACKGROUND: Image-guided radiotherapy (IGRT) is a novel technology to enhance RT delivery accuracy. However, the clinical effectiveness and cost-effectiveness are less clear. The aim of our study is to compare the cost and effectiveness of conventional fractionated RT for non-operated localized lung cancer delivered with vs. without IGRT via this population-based propensity score (PS) matched analysis. METHODS: We identified eligible patients diagnosed within 2007-2010 through a comprehensive population-based database containing cancer, death registries, and reimbursement data in Taiwan. The primary duration of interest (DOI) was 2 years within diagnosis. Effectiveness was measured as survival whereas direct medical cost was measured from the payers' perspective. In supplementary analysis (SA), we estimated the cost-effectiveness in consider of out-of-pocket (OOP) payment and 4 years as DOI. RESULTS: Our study population constituted 124 patients. Within 2 years, both the mean cost (2014 USD) and survival (life-year, LY) were higher for IGRT ($60,774 vs. $60,554; 1.43 vs. 1.37). The incremental cost-effectiveness ratio (ICER) when IGRT was compared to non-IGRT was 3,667 (USD/LY). The chance for IGRT to be cost-effective was around 68% & 70% at willingness-to-pay threshold 50,000 USD/LY and 150,000 USD/LY respectively. IGRT remained cost-effective in SA. CONCLUSIONS: We provide the first empirical evidence that when compared to non-IGRT, IGRT was potentially cost-effective.
Entities:
Keywords:
Cost effectiveness analysis; image-guided radiotherapy (IGRT); lung cancer
Authors: D Shumway; K Corbin; R Salgia; P Hoffman; V Villaflor; R M Malik; D J Haraf; W T Vigneswaren; A Y Shaikh; P P Connell; M K Ferguson; J K Salama Journal: Lung Cancer Date: 2011-06-14 Impact factor: 5.705
Authors: Peter Goldstraw; David Ball; James R Jett; Thierry Le Chevalier; Eric Lim; Andrew G Nicholson; Frances A Shepherd Journal: Lancet Date: 2011-05-10 Impact factor: 79.321
Authors: Michaela A Dinan; Lesley H Curtis; William R Carpenter; Andrea K Biddle; Amy P Abernethy; Edward F Patz; Kevin A Schulman; Morris Weinberger Journal: J Thorac Oncol Date: 2014-04 Impact factor: 15.609